Showing 8401-8410 of 10255 results for "".
- Immune and BioNanoSim Enter Agreement to Develop Novel Topical Nano-Capsule Formulation of Cyclosporinehttps://practicaldermatology.com/news/immune-and-bionanosim-enter-agreement-to-develop-novel-topical-nano-capsule-forumlation-of-cyclosporine/2458768/Immune Pharmaceuticals Inc. entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd. for a novel topical nano-capsule formulation of cyclosporine, also known as cyclosporine-A or CsA. Monica Luchi, M.D., Chief Medical Officer of Immune, commented: "
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor
- Galderma and ZELTIQ Announce US Collaboration in Aestheticshttps://practicaldermatology.com/news/galderma-and-zeltiq-announce-us-collaboration-in-aesthetics/2458785/Galderma and ZELTIQ Aesthetics, Inc. entered into a new collaboration across the companies’ innovative aesthetic brands and offerings. Effective immediately, the creation of this nationwide collaboration will provide healthcare professionals and consumers with greater access to a robust ran
- Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointmenthttps://practicaldermatology.com/news/aqua-pharmaceuticals-acquires-us-rights-to-veltin-gel-and-altabax-ointment/2458795/Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and
- AAD Releases New App to Aid Patients with Chronic Hiveshttps://practicaldermatology.com/news/aad-releases-new-app-to-aid-patients-with-chronic-hives/2458798/The American Academy of Dermatology (AAD) released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. The free mobile app, developed with a grant from Novartis Pharmaceuticals Corp., can help patients learn more about their condition, find a doctor, trac
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Agents for Advanced Melanoma Among Prix Galien USA 2015 Award Recipientshttps://practicaldermatology.com/news/agents-for-melanoma-among-prix-galien-usa-2015-award-recipients/2458832/The Prix Galien USA 2015 Awards have been bestowed on Imbruvica® (ibrutinib) for best pharmaceutical agent, Opdivo® (nivolumab) and Keytruda® (pembrolizumab) for best biotechnology product, and the T2Candida Panel for best medical technology. 
- FDA Approves Juvederm® Ultra XC for Use in Lipshttps://practicaldermatology.com/news/fda-approves-juvederm-ultra-xc-for-use-in-lips/2458860/Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation
- Suneva Medical: Bellafill Study is Largest, Longest Post-market Clinical Evaluation of Dermal Fillerhttps://practicaldermatology.com/news/suneva-medical-bellafill-study-is-largest-longest-post-market-clinical-evaluation-of-dermal-filler/2458874/Billed as the largest and longest post-market clinical evaluation of a dermal filler, a new study reported by Suneva Medical shows high levels of patient satisfaction and favorable safety outcomes with Bellafill five-years post-treatment. With an 87 percent retention rate, the study showed that a
- AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumabhttps://practicaldermatology.com/news/astrazeneca-and-valeant-pharmaceuticals-to-partner-on-brodalumab/2458881/AstraZeneca and Valeant Pharmaceuticals International, Inc. entered into a collaboration agreement under which AstraZeneca will grant Valeant an exclusive license to develop and commercialize brodalumab, an IL-17 receptor monoclonal antibody that is in development for patients with moderate